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The aim of this study is to establish the frequency of unlicensed and off label drug use in
infants admitted to the neonatal intensive care unit (NICU) in Tygerberg Hospital.
METHOD
This was a prospective descriptive survey conducted over 3 consecutive months (September
2011-November 2011) of all medicine charts of neonates admitted during this time period to
the NICU. Data collected included demography, diagnoses, medicines prescribed according
to dose, frequency, route of administration and indication. Medicine use was defined as
unlicensed, licensed or off label use according to the latest South African Medicines
Formulary (2012) and the manufacturer’s package insert. Unlicensed drug use is per
definition a drug not registered with South African Medicine Control Council (SA MCC) for
children and off label drug use is where the use is outside of its authorized license with SA
MCC.
RESULTS
There were 112 neonates enrolled in the study, of whom 51% were preterm and 49% term
infants. The most common diagnoses on admission for the preterm babies were hyaline
membrane disease (33%) and sepsis (21%), while it was hypoxic ischemic encephalopathy
(42%) and post-operative care (22%) for term infants. There were 759 drug events of which
37% were licensed and followed all the licensing terms, 51% were prescribed in an off label
manner and the remaining 12% were of unlicensed drugs. The most common reasons off
label drug use were for weight (74%), followed by age (44%), frequency (44%), indication
(21%), or a route not described in the licensing terms (13%). There was a lack of pediatric
data for 9% of the drugs prescribed. In 203 drug events (27%) a drug was used in an off label
manner for more than one reason. Sixty one percent of the drugs used had no information on
the use of the drug in neonates.
CONCLUSION
This is the first study conducted in an African NICU, according to our knowledge and the
results are similar to studies conducted in Europe and America. Neonates are exposed to a
vi
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significant proportion of unlicensed and off label drugs. Neonatal clinical trials should be
conducted to address the need for proven safe and efficacious treatment for neonates.
vii
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This is the term for a new-born up to chronological age of 28 days after birth.
 
Gestational age:
This refers to the time period between conception and birth.
Premature:
This is the term used for a baby born at less than 37 weeks gestational age.
Term:
This refers to a baby born between 38 and 42 weeks gestational age.
Chronological age:
This refers to the time period after birth.
HIV exposed:
Babies who were born to Human Immunodeficiency Virus infected women.
Pharmacokinetics:
This is the study of the mechanism by which a drug is absorbed, distributed, metabolized and
eliminated in the body.
Pharmacodynamics:
This is the study of the effects of a drug on the body.
Off label:
Refers to a drug that is used differently to the instructions given in the package insert or the
way the drug is registered to be used. This can be in terms of weight, age, indication, lack of
pediatric data, route of administration and frequency. 
ix
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This is a drug that is used before it is registered with the licensing authority of a country. If a
registered drug is reformulated, it is then also considered as an unlicensed drug.
Extemporaneous compounding:
This refers to a drug that is converted from one form to another in order for easier
administration to the patient, and thus changing some of its properties. For example, a tablet
form of a drug is crushed and mixed with a liquid medium so children can easily swallow it.
Special formulations:
These are drugs, already licensed in one form, but specially reformulated under a special
license and changed to another form.
x
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1. Introduction
1.1. Literature Review
There is a high incidence of the use of off label and unlicensed drugs in children, as
documented in North America and Europe, but little has been documented from Africa.1
The neonate population receives the majority of unlicensed drugs and off label drugs and
is often excluded from clinical drug trials due to the vulnerability of this group. 2 The
majority of the drugs are essential for the treatment of the neonates and there is no
alternative medication available. 3 
Drug licensing was first introduced in the United States of America (USA) after the
tragedies that took place in the 1960’s. 4 Pregnant women were given thalidomide for
morning sickness during their pregnancy and this resulted in their children being born with
phocomelia. New-born babies, who received intravenous chloramphenicol, developed
“grey baby” syndrome because they did not have the necessary enzymes to metabolize
the drug. 5 Subsequently the USA established a statutory body to regulate medicines
control and for registration of medicines after they had been proven to be safe for use. In
the USA it is the Food and Drug Administration (FDA), in Europe the European Medicines
Agency (EMEA) and in South Africa the Medicines Control Council (MCC) that has the
authority of licensing a drug .6-8 
There is a general lack of neonatal clinical drug trials mainly due to the vulnerability of
neonates and small incentives for pharmaceutical companies to change a product licence
of a drug that is already in use. 9 Many practitioners are forced to use off label drugs
because there are no alternative drugs for children and the practice is acceptable provided
the practitioner can prove that it was based on expert medical judgment in the best
interests of the patient. 10, 11 
A study done in France showed that there is an increased risk of adverse drug reactions
with the use of off label drugs in a pediatric setting.12 Most of these drugs have only been
tested in adults and are now being given to children. The pharmacokinetics and
pharmacodynamics of drugs in children differ from that of adults.13 This means that the
absorption, metabolism and clearance of a drug are different in neonates compared to that
in adults. Reasons for this include an immature gut, liver and kidneys in neonates, which
1
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results in slower absorption, metabolism and excretion. Compared to adults, newborns
 
have delayed gastric emptying and decreased gastric acid secretion. Drugs that are acid
labile (example: penicillin) will therefore have an increased bioavailability than drugs that
are weakly acidic (example: phenobarbitone). Neonates also have lower albumin levels
and lower protein binding capacity, which influences drug availability. The rate of blood
flow to the kidneys is approximately 10 times lower at birth compared to an adult. This will
delay renal excretion of some drugs such as theophylline and increase their half-life. The
percentage of body water content also causes differences in the volume of distribution of
drugs like aminoglycosides. The water content is the highest in preterm neonates (80%)
compared to term (70%) and even less in adults (60%). In a similar way, the
pharmacodynamics and pharmacokinetics differs between preterm neonates, term
neonates and infants, and gestational age must be taken into consideration when
prescribing drugs. 13 
In the case of unlicensed drugs that are extemporaneously compounded, there is an
increased risk of having errors in calculation, incorrect quantities mixed and inappropriate
medium used, especially if not done by a qualified experienced pharmacist. This could
result in an unstable product that could have fatal consequences and a short shelf life .14, 15 
It is essential to prove that potentially efficacious drugs are safe in children and there
should be guidelines on how they should be administered. This can be done in two ways:
The manufacturers can be encouraged to do clinical trials to determine the safety and
efficacy of drugs in children, which can be motivated by establishing a national pediatric
pharmacology research unit where the trials can be conducted. 9 Alternatively the safe use
of off- label drugs can be promoted via case presentations, medical literature, conferences
and expert advice from colleagues. 7 The first option is the ideal solution, but it is
considered to be time consuming and expensive. Legislation is one option to ensure that
the necessary drug studies are conducted in vulnerable populations to ensure that they
also benefit from better medicines.16 The USA took the lead in 1997 when the FDA
provided a 6 month extension of patent protection of medicines and later in 1999
established the ‘Pediatric rule’ which made it a requirement that all the new drugs to be
released into the market, had to be first tested in children. It was the “Best
pharmaceuticals for children’s Act” in 2002 that made the provision for the study of
neonatal medicine. Europe followed in the same year by releasing a document entitled
“Better medicines for children” which later became legislation, demonstrating the European
2
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Union’s commitment to the issue.16 Similar steps are yet to be taken by the rest of the
world.
It is very important that parents are educated about off label and unlicensed use of drugs
as most parents are not even aware of this practice. 17 It has been suggested by an article
by Lenk, et al. that the best way to encourage our parent population to enrol their children
into clinical trials will be by educating the parents about how common the use of off label
drugs is and of how much value there is in the clinical trials.17 It is also important to
educate the medical practitioners of the experiences of their peers with the use of off label
and unlicensed drugs so that a standard accepted form of treatment takes place. This can
be done in a medical newsletter designed for this sole purpose, making it easier for
practitioners to stay updated. 17
In South Africa the Medicines and Related Substances Act 101 of 1965 and Regulation 45
do not allow pharmaceutical companies to disperse any information (written or oral)
regarding off label use of a medicine to the public or other medical practitioners. 7 This
would mean that South African doctors have limited resources for information on off label
and unlicensed use of drugs in pediatrics. In countries like India, it is even illegal to
prescribe off label and unlicensed drugs. 16 Despite this, the practice of off label drug use
continues and most physicians are not even aware that they are doing so. The only way
that a physician can ensure that he is not faced with litigation because of adverse effects
from a drug used in an off label manner is to ensure that these drugs are safe through
clinical trials.18 The first step is to create awareness of this practice and its extent. There is
currently only limited data from Africa and this study was done to show that this is not just
a problem in Europe and United States of America, but that Africa is just as equally
affected and therefore also needs to be part of a solution.
3





                  
               
          
 
   
                 
             
 
 
   
                 
 


















The aim of this study is to determine the use of unlicensed and off label drugs to neonates
in the neonatal intensive care unit (NICU) setting in an academic hospital in South Africa,
and to identify the drugs commonly used in this manner.
2.1. Primary Objectives
•	 To determine the use of unlicensed and off label drugs in NICU over 3 months, with
regards to weight, age, indication, lack of pediatric data, route of administration and
frequency.
2.2. Secondary Objectives
•	 To create a greater awareness of this practice of off label and unlicensed drug use in
neonates.
•	 To promote the ruling that all new drugs should undergo drug trials in neonates before
acquiring licensing.
4





             
             
            
              
                 
               
 
               
               
              
             
             
             
              
    
 
               
              
             
            
              
     
 
           
     
   
              
            
         
3. Methodology
 
This was a prospective descriptive survey. The study population included all the neonates
admitted to NICU at Tygerberg Hospital, an academic tertiary hospital in Cape Town,
South Africa. This study was conducted over three consecutive months, September 2011
to November 2011, and data was updated daily during this period. The Tygerberg Hospital
NICU is able to accommodate 12 babies at the same time, with 8 beds dedicated for the
critically ill and 4 beds dedicated for those patients that need only high care.
A waiver of consent was obtained from the ethics committee as the data from each
patient’s file was linked to a unique study number, and no identifiable data was collected.
Demographic data was collected for each patient that comprised of the age, weight, sex,
and diagnosis. Details of their prescription were obtained from the prescription charts and
included the dose, frequency, indication, and route of all medicines prescribed per patient
and categorized as licensed, unlicensed or off label for age, weight, frequency, indication
and route of administration. Two patients were readmitted during the period of study and
therefore sampled twice.
The unlicensed drugs fell into 3 categories. The first category included the drugs that were
already licensed in one form and then specially reformulated under a special licence and
changed to another form, while the second category included licensed drugs that were
extemporaneously compounded (tablet form crushed and mixed with water to form a
suspension) and the third category was for imported drugs licensed for use in another
country, but not South Africa.
The Health Research Ethics Committee of Stellenbosch University approved the protocol
(ethics reference no: n11/07/214).
3.1. Inclusion criteria
A neonate that was admitted to Tygerberg Hospital NICU during the period of data
collection (September 2011 to November 2011), and had received some form of
medication during the stay, was included in the study.
5
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3.2. Exclusion criteria
Babies who were older than 28 days or whose corrected gestational age was greater than
1 month, were not included in the study, as well as neonates not receiving any medication.
6
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4. Results 
4.1. Demographics 
During the 3-month study period, 117 patients were admitted to NICU. Of these, 112 were 
enrolled in the study. Five patients were excluded, because they did not fit the inclusion 
criteria: namely 2 babies were dead on arrival in the NICU, 2 were only admitted for blood 
exchange transfusion and 1 baby with Trisomy 13 died soon after admission who had not 
received any medication from NICU. More than half (51%) of the neonates were premature 
(figure 1 ). The preterm babies had a mean gestational age of 32 weeks (median age of 32 
weeks; range 27 to 36 weeks). The mean age was 18.9 days (median age 10 day, range: 
2 to 73 days). The male to female ratio was 1 :0.7. 





Term patients; Premature patients; 




Gestational Chronological Gestational Chronological 
Age Age 
age (Weeks) age (Days) age (Weeks) age (Days) 
Mean 37.6 1.3 Mean 32 18.9 
Median 37 1 Median 32 10 
Range 37-45 1-2 Range 27-36 2-73 
7 
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4.2. Diagnoses: 
The primary diagnoses of the premature babies were hyaline membrane disease {33%), 
sepsis (21 %), necrotizing enterocolitis (14%), post-operative care (1 0%), hypoxic ischemic 
encephalopathy {9%), congenital structural abnormality {5%), pneumonia {2%), meconium 
aspiration syndrome {2%), early neonatal jaundice {2%) and congenital syphilis {2%) in 
descending order (figure 2). 
Figure 2: The most common diagnoses of the premature babies 
Premature: Primary Diagnosis 
1 1 1 
• Hyaline Me mbrane 
Disease 
• Se psis 
• Necrotizing Ente rocolitis 
• Post Operative Care 
• Hypoxic lschaemic 
Encephalopathy 
• Congenit al Struct ural 
Abnormalities 
• Pneumonia 
• Congenital Syphillis 
Me conium Aspirat ion 
Syndrome 
• Neonatal Jaundice 
For the term babies, the mean gestational age was 37. 6 weeks (median age of 37 weeks, 
range 37 to 45 weeks). The chronological mean age was 1.3 days (median age of 1 day, 
range 1 to 2 days). The male to female ratio was 1 :0.8. Hypoxic ischemic encephalopathy 
was the most common diagnosis in term neonates {42%), followed by post-operative care 
(22%), congenital structural abnormality {11%), sepsis {7%), meconium aspiration 
syndrome (5%), pneumonia {5%), congenital cardiac lesion {4%), early neonatal jaundice 
{2%) and congenital syphilis .{2%). (Figure 3) Twenty-seven babies of the 112 were 
diagnosed as HIV exposed and the majority of these exposed infants were term babies {63 
%) and the rest {37%) were preterm. 
8 
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Figure 3: The most common diagnoses of the term babies 
Term: Primary Diagnosis 
1 
4.3. Drugs: 
• Hypoxic lschaemic 
Encephalopathy 
• Post Operative Care 
• Conge nita! Structural 
Abnormalities 
• Sepsis 
• Meconium Aspiration 
Syndrome 
• Pneumonia 
Congenitial Cardiac Lesion 
Early Neonatal Jaundice 
Conge nita I Syphilis 
There were 759 drug events in the study population with 7 4 different drugs prescribed 
during the data collection period, excluding fluids, blood products and mineral 
supplements. Each patient received between 1 to 26 different drugs per admission. The 
majority (88%} of the prescriptions were licensed drugs, of which 51% were used off label 
and 12% were unlicensed. (Figure 4) 
9 
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The most common reason for off label use per drug events was due to a different dose 
prescribed for the recommended weight {74%}, followed by drugs inappropriately 
prescribed for age {44%}, frequency (21 %}, indication (21%}, for a route not described in 
the licensing terms {13%} or absence of pediatric data {9%}. 
For the 203 drug events, a drug was used in an off label manner for two or more reasons 
in 27% drug events. One hundred and two patients {91 %} received at least one unl icensed 
or off label drug during their admission to the NICU. 
The 10 most commonly prescribed drugs were penicillin {9%}, gentamycin (7 .6%} 
aminophylline (7.2%}, meropenem (7.1%}, vancomycin (6.7%}, phenobarbitone (4%}, 
paracetamol {3.8%}, tilidine (3.6%}, vitamin K (3.3%} and glycerine suppositories (3%}. 
(Table 1 ). 
10 
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Table 1: The 10 most commonly prescribed drugs 
Drug No of prescription episode Percentage 
Penicillin 70 9 
Gentamycin 58 7,6 
Aminophylline 55 7,2 
Meropenem 54 7,1 
Vancomycin 51 6,7 
Phenobarbitone 30 4 
Paracetamol 29 3,8 
Tilidine 27 3,6 
Vitamin K 25 3,3 
Glycerine suppository 23 3 
The five drugs, that were most frequently prescribed in an off label or unlicensed manner, 
were aminophylline, meropenem, vancomycin, intravenous paracetamol (Perfalgan®) and 
tilidine (Valoron®) in descending order (Table 2). Only two anti-retroviral drugs were 
prescribed to the neonates (nevirapine and zidovudine) and they formed 3.5% of the total 
prescriptions. Both were given in an off label manner. The anti-tuberculosis drugs formed a 
very small proportion (0.5%) of the total number of prescription and were only prescribed 
to two patients. The three anti-tuberculosis drugs prescribed were Rifampicin, Isoniazid 
and Pyrazinamide. Rifampicin was given in an off label manner while Isoniazid and 
Pyrazinamide were part of the "special formulation" made by the pharmacy and therefore 
unl icensed. 
Table 2: The most commonly prescribed drugs in an off label or unlicensed manner 
Drug No. of Prescriptions Status 
Aminophylline 55 (7%) Off- label for age 
Meropenem 54 (7%) Off- label for age 
Vancomycin so (7%) Off- label for dose 
Tilidine 27 (4%) Off- label for age 
Paracetamol (ivi) 25 (3%) Off- label for age 
The unlicensed drugs fell into 3 categories with the majority of the drugs under the "special 
formulations" (84%) category, followed by extemporaneously compounded drugs (1 0%) 
and imported drugs (6%). (Figure 5) 
11 
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The drugs were also classified into drug groups according to the latest Anatomical 
Therapeutic Chemical (ATC) classification, suggested by the World Health Organization. 
The most prescribed drugs were anti-infectives for systemic use {41.4%}, followed by 
drugs for the nervous system (20%}, alimentary tract and metabolism {9.6%}, respiratory 
tract {9.3%}, cardiovascular system {8.3%}, blood and blood forming organs {3.3%}, 
musculoskeletal (3.3%}, systemic hormonal preparations (2.5%}, genito-urinary system 
and sex hormones {0.9%}, anti-parasitic products {0.8%}, sensory organs {0.4%} and a 
few other drugs {0.1%). (Table 3} 
12 
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Table 3: Drug categories according to ATC Classification
 










A Alimentary tract and metabolism
A02 drugs for acid related disorders
Proton pump inhibitors A02BC Omeprazole 4 4 Dose
H2-receptor antagonists A02BA Cimetidine 15 11
Frequency,
Dose





A07 antidiarrheal, intestinal anti-inflammatory/anti-infective agents




A10 drugs used in diabetes
Insulins and analogues for
injection, fast-acting
A10AB Insulin short acting 3 0
A11 vitamins
Vitamin D and analogues A11CC Vitamin D 9 0
A16 other alimentary tract and metabolism products
Amino acids and
derivatives
A16AA L-carnitine 1 0 Unlicensed
B Blood and blood forming organs
B02 antihemorrhagics







Dobutamine 12 12 Dose
Adrenaline 8 1 Dose






C01EB Adenosine 1 1 Dose
C03 diuretics
13
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Aldosterone antagonists C03DA Spironolactone 2 1 Dose
Thiazides, plain C03AA Hydrochlorothiazide 1 1 Dose
Sulfonamides, plain C03CA Furosemide 17 10
Indication,
frequency, dose
C09 agents acting on the renin-angiotensin system




G Genito urinary system and sex hormones
G02 other gynecologicals






Drugs used in erectile
dysfunction





H Systemic hormonal preparations, excl. sex hormones and insulins
H02 corticosteroids for systemic use













J.Anti-infective for systemic use
J01 Antibacterials for systemic use
Carbapenems J01DH Meropenem 54 54
Age, frequency,
dose

















     





      
  
 









    
 
 
   
 
     
   
     
     
      
       
       




    
  
 
      
     
    
            
  
   
  
 
     
    
   
  
 





      
     
      
 
 
     










J01DC Cefuroxime 1 0
Beta-lactamase resistant
penicillins


















Polymyxins J01XB Colistin 3 0 unlicensed
Other antibacterials J01XX Linezolid 1 1 Frequency
Fluoroquinolones J01MA Ciprofloxacin 3 2 Indication, dose








Rifampicin 2 2 Route
















J05AG Nevirapine 20 12 Dose, route
J02 antimycotics for systemic use
Triazole derivatives J02AC Fluconazole 16 10
Frequency,
dose
J06 immune sera and immunoglobulins
Specific immunoglobulins J06BB Palivizumab 1 0
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M03AC Pancuronium 2 2 Dose
Choline derivatives M03AB Suxamethonium 15 0















Bupivacaine 2 2 Dose
Lignocaine 1 1 Indication




Other general anesthetics N01AX Ketamine 18 0
N06 psychoanaleptics
Xanthine derivatives N06BC Caffeine 9 0 Unlicensed
N02 analgesics
Other opioids N02AX Tilidine (valoron) 27 27 Age, dose





N02CX Clonidine 1 1 Age, indication
Natural opium alkaloids N02AA Morphine 1 1 Dose
N03 antiepileptics
Hydantoin derivatives N03AB Phenytoin 2 1 Dose
Barbiturates and
derivatives
N03AA Phenobarbitone 30 3 Dose
P Antiparasitic products, insecticides and repellents
P01 antiprotozoals
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R01 nasal preparations





R03 drugs for obstructive airway diseases
Xanthines R03DA Aminophylline 55 55
Age, indication,
frequency
R07 other respiratory system products







Poractant alfa 10 3 Dose, Indication
Beractant 2 2 Dose
S Sensory organs
S01 ophthalmologicals




Anticholinergics S01FA Cyclomydril 2 0
V Various
V03 all other therapeutic products
Drugs for treatment of
hypoglycemia
V03AH Diazoxide 1 0 Unlicensed
17





                
            
             
                 
             
               
               
               
        
 
                 
               
                 
                   
               
                 
                  
               
                
                
           
  
             
             
            
               
5. Discussion
The use of drugs in children, based on drug trials conducted in adults and extrapolated to
children, shows ignorance of the important differences that exist in the pharmacokinetics
and pharmacodynamics of drugs between adults and children. 19 The extent of unlicensed
and off label drug use in pediatrics has been well highlighted since the 1960’s in the US
and Europe. This has subsequently resulted in changes made by the respective authorities
in facilitating drug trials in children to improve the access to safe and efficacious medicines
for children. Studies in Australia, as well as the United Kingdom have shown a higher
incidence of unlicensed and off label drug use in NICUs compared to drug use among
pediatric patients in general medical and surgical wards.9 
This study is the only one reported from a NICU in Africa and our results regarding the
proportion of unlicensed and off label drugs (12% and 51% respectively) are similar to that
reported by Dell’Aera et al. (12.0% and 50.5%) in 2004 in an Italian NICU, 5 O’Donnell et
al. (11% and 47%) in 2002 in Australia 19 and Conroy et al. (9.9% and 54.7%) in 1999 in
United Kingdom. 16 In this study 91% of neonates, admitted over the 3 month period,
received at least one off label or unlicensed drug, which was similar to the results in the
review by Cuzzolin et al, where more than 80% of neonates are exposed to at least one off
label or unlicensed drug. 16,20 The main reason for off label drug use was inappropriate
dosing for the recommended weight; this is similar to the findings in the study by Conroy,
et al, but different from the findings by O’Donnell, et al in Australia where the most
common reason for off label drug use was for indication. 19,20 
Aminophylline was the most commonly prescribed drug in an off label or unlicensed
manner. Aminophylline, theophylline and caffeine belong to the group of drugs known as
methylxanthines and have been used to reduce apnoea and stimulate breathing.
Aminophylline is registered for use in pediatrics, but only for children older than 6 months
18
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of age. 21Recurrent apnoea is a common problem among the preterm babies and a
Cochrane review in 2010 by Hendersen-Smart, et al, demonstrated that methylxanthine
was effective in reducing apnoea in premature infants. 22 Caffeine is unlicensed in South
Africa, as well as in Europe, and yet it is considered the safest of the methylxanthines for
the treatment of apnoea of prematurity. 23 Another drug that was used in our setting for the
treatment of apnoea of prematurity is doxapram, a stimulant of the respiratory centre in the
brain. This drug is contraindicated in neonates in Japan because of its side effects, yet its
use continues in many parts of the world, with only a few studies done to investigate its
use in neonates. 24 Hendersen-Smart, et al. only found 1 randomized control trial (RCT) in
a Cochrane review from 1966 to April 2009, which indicates that doxapram may reduce
apnoea in the first 48 hours of treatment, but it was a small study with a wide confidence
interval and long-term outcomes were not measured. Therefore the conclusion was that
more studies are needed to confirm the role of doxapram for the treatment of apnoea in
preterm infants. 25 
The antibiotic, most frequently used in an off label manner in our study was the
intravenous form of meropenem. This carbapenem has been used in neonates to treat
severe infections due to gram-negative or gram-positive organisms, including nosocomial
infections, although safety and efficacy in children less than 3 months of age has not yet
been established. 26 
Meconium retention in low birth weight infants causes bowel dysfunction. 27 Significant
delays to pass meconium have been observed in preterm babies compared to term
babies. A glycerine suppository, which was among the 10 most commonly prescribed
drugs in our study, is used to stimulate passage of meconium and reduce feeding
intolerance. According to a review done by Shah et al in 2007, the evidence was
inconclusive regarding the effectiveness of glycerine suppositories for improving feeding
intolerance in preterm babies. 28 This review was done based on two studies, including a
randomized control study, which showed no benefit and an observational cohort study,
19
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which showed benefit in terms of achieving full feeds earlier with reduced sepsis due to
deep lines for enteral feeds. 28 This is a clear indication that more studies are needed to
make a proper decision.
Although the anti-tuberculosis drugs only formed a small proportion (0.5%) of our total
prescriptions, it was given in off label or unlicensed manner. The highest rate of this global
pandemic of tuberculosis (TB) occurs in sub-Saharan African countries and goes hand in
hand with the HIV epidemic. 29 As the trend goes, children were left out of the initial series
of clinical trials for TB treatment and have been receiving drug doses extrapolated from
adult doses. It only became evident in 2007 that the children were under dosed and that
drugs like isoniazid had to be doubled in dose when given to children to achieve the same
isoniazid concentration in adults. 30 Children however are still not receiving the right doses
because the formulations of anti-TB drugs are not pediatric friendly. The anti-TB drugs
used in this study and the available formulations at Tygerberg Hospital include the fixed
drug combination tablets, single drug tablets, and capsules. Although a syrup formulation
is more suitable for pediatrics, it is not commercially available. The Tygerberg pharmacy
makes its own syrup for drugs like isoniazid, using a complex recipe. This formulation is
only stable for a limited period and is not available to surrounding clinics including the TB
hospital in the region.
In this study only two antiretroviral drugs (ARV) to prevent mother to child transmission of
HIV were used and they made up 3.5 % of the total prescriptions. Both are available in
solution form and therefore easier to administer to the neonates. They were both used in
an off- label manner because of dose and frequency different to the recommendations in
the SAMF and the ARV dosing chart for children and adolescents by the South African HIV
Clinicians Society. It is important to note that there were variations between the two
references regarding the recommendations in children <3kg.31 There has been a renewed
interest in anti-tuberculosis drugs and ARVs in the last couple of years which has resulted
in a deliberate effort by pharmaceutical companies to produce these drugs in a more
20
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tolerable form that would be easier to administer. There are concerns raised about
whether clinical trials are ethical in neonates considering the informed consent, assent and
risks involved versus potential benefit. 9 What is certain is that it is more unethical to give
drugs that have not been proven to be safe and efficacious to neonates.19
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6. Limitations:
It was difficult to compare studies done in similar settings because the definitions of
unlicensed and off label drugs differed between the authors. The number of prescriptions
for drugs like fentanyl, dopamine and dobutamine may have been more than what was
recorded in the study, as some of these prescriptions may erroneously been written on the
fluid chart instead of the drug chart. The results in this study were similar to that published
from Europe and the United States of America since Tygerberg Hospital NICU offers top
services for neonatal care in South Africa and may therefore differ to other neonatal
services provided by the different levels of health care in other countries in Africa. The
period of 3 months for this study might not have been sufficient to represent the
generalized population. Prescription errors may have affected the off label results, for
example prednisone was wrongly prescribed to be given intravenously but it was given per
os.
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Children should be afforded the same importance and chance as adults when it comes to
receiving safe and efficacious drugs. It is the role of regulatory authorities to pressurize
pharmaceutical companies to perform clinical trials in children. The USA and Europe have
taken the first steps already, an example that should be followed by the rest of the world.32 
Practical, legislative and ethical difficulties do exist with pediatric clinical trials, but the
improvement in health and safety of all children should be our responsibility and is it
therefore important to conduct clinical trials in neonatology for drugs seen as essential to
improve their health.
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